Cargando…
Interleukin 2-Based Fusion Proteins for the Treatment of Cancer
Interleukin 2 (IL-2) plays a fundamental role in both immune activation and tolerance and has revolutionized the field of cancer immunotherapy since its discovery. The ability of IL-2 to mediate tumor regression in preclinical and clinical settings led to FDA approval for its use in the treatment of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592747/ https://www.ncbi.nlm.nih.gov/pubmed/34790830 http://dx.doi.org/10.1155/2021/7855808 |
_version_ | 1784599536795123712 |
---|---|
author | MacDonald, Alana Wu, T.-C. Hung, Chien-Fu |
author_facet | MacDonald, Alana Wu, T.-C. Hung, Chien-Fu |
author_sort | MacDonald, Alana |
collection | PubMed |
description | Interleukin 2 (IL-2) plays a fundamental role in both immune activation and tolerance and has revolutionized the field of cancer immunotherapy since its discovery. The ability of IL-2 to mediate tumor regression in preclinical and clinical settings led to FDA approval for its use in the treatment of metastatic renal cell carcinoma and metastatic melanoma in the 1990s. Although modest success is observed in the clinic, cancer patients receiving IL-2 therapy experience a wide array of side effects ranging from flu-like symptoms to life-threatening conditions such as vascular leak syndrome. Over the past three decades, efforts have focused on circumventing IL-2-related toxicities by engineering methods to localize IL-2 to the tumor or secondary lymphoid tissue, preferentially activate CD8(+) T cells and NK cells, and alter pharmacokinetic properties to increase bioavailability. This review summarizes the various IL-2-based strategies that have emerged, with a focus on chimeric fusion methods. |
format | Online Article Text |
id | pubmed-8592747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-85927472021-11-16 Interleukin 2-Based Fusion Proteins for the Treatment of Cancer MacDonald, Alana Wu, T.-C. Hung, Chien-Fu J Immunol Res Review Article Interleukin 2 (IL-2) plays a fundamental role in both immune activation and tolerance and has revolutionized the field of cancer immunotherapy since its discovery. The ability of IL-2 to mediate tumor regression in preclinical and clinical settings led to FDA approval for its use in the treatment of metastatic renal cell carcinoma and metastatic melanoma in the 1990s. Although modest success is observed in the clinic, cancer patients receiving IL-2 therapy experience a wide array of side effects ranging from flu-like symptoms to life-threatening conditions such as vascular leak syndrome. Over the past three decades, efforts have focused on circumventing IL-2-related toxicities by engineering methods to localize IL-2 to the tumor or secondary lymphoid tissue, preferentially activate CD8(+) T cells and NK cells, and alter pharmacokinetic properties to increase bioavailability. This review summarizes the various IL-2-based strategies that have emerged, with a focus on chimeric fusion methods. Hindawi 2021-11-08 /pmc/articles/PMC8592747/ /pubmed/34790830 http://dx.doi.org/10.1155/2021/7855808 Text en Copyright © 2021 Alana MacDonald et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article MacDonald, Alana Wu, T.-C. Hung, Chien-Fu Interleukin 2-Based Fusion Proteins for the Treatment of Cancer |
title | Interleukin 2-Based Fusion Proteins for the Treatment of Cancer |
title_full | Interleukin 2-Based Fusion Proteins for the Treatment of Cancer |
title_fullStr | Interleukin 2-Based Fusion Proteins for the Treatment of Cancer |
title_full_unstemmed | Interleukin 2-Based Fusion Proteins for the Treatment of Cancer |
title_short | Interleukin 2-Based Fusion Proteins for the Treatment of Cancer |
title_sort | interleukin 2-based fusion proteins for the treatment of cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592747/ https://www.ncbi.nlm.nih.gov/pubmed/34790830 http://dx.doi.org/10.1155/2021/7855808 |
work_keys_str_mv | AT macdonaldalana interleukin2basedfusionproteinsforthetreatmentofcancer AT wutc interleukin2basedfusionproteinsforthetreatmentofcancer AT hungchienfu interleukin2basedfusionproteinsforthetreatmentofcancer |